Mechanism of antifungal action of Pichia proteins
毕赤酵母蛋白的抗真菌作用机制
基本信息
- 批准号:9422694
- 负责人:
- 金额:$ 39.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-14 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAdherenceAffectAffinity ChromatographyAgeAmmonium SulfateAntibioticsAntibodiesAntifungal AgentsApoptosisAspergillusBiological AssayCandidaCell membraneChromatographyClinicalComplicationCryptococcusDataDiabetes MellitusDiseaseDoseEndopeptidase KEnzymesEthnic OriginEvaluationExhibitsExposure toExtravasationFluconazoleFractionationFusariumGerminationGlucansGrowthHIVHistologicImmunocompromised HostIn VitroIndividualInfantInfectionIon ExchangeLectinMalignant NeoplasmsMediatingMethodsMicrobial BiofilmsMorphologyMycosesNatureNystatinOralOral CharactersOral candidiasisOrganismOxidative StressParticipantPathogenesisPathogenicityPatientsPenicilliumPepstatinsPeptide HydrolasesPichiaPreventionProtease InhibitorProteinsProteomicsRisk FactorsSepharoseSerine ProteaseSubstrate SpecificityTemperatureTissuesTongueTopical applicationTranscription Factor 3Western BlottingYeastsaspergillopepsin IIbacteriomecohortefficacy testingfungusin vivoinhibitor/antagonistinsightliquid chromatography mass spectrometrymembermicrobiotamouse modelmycobiomenoveloral bacteriaoral careoral fungaloral microbiomeplant fungiproteinase Inpublic health relevancesexstandard of caretreatment duration
项目摘要
DESCRIPTION (provided by applicant): Oral candidiasis (OC, caused by Candida) is a major complication in immunosuppressed patients, including those infected with HIV, cancer, and diabetes, as well as infants. One of the risk factors for OC is the use of antibiotics, which is known to alter the microbial flora. Interactions between Candida and members of the oral microbiome have not been investigated. We performed preliminary studies to: (a) characterize the oral bacterial microbiome (bacteriome) and oral fungal microbiome (mycobiome), and (b) determine whether changes in bacteriome/mycobiome affect Candida colonization. We showed: (1) core oral bacteriome (COB) comprises 14 genera in HIV-infected and uninfected individuals, of which 13 were common, (2) core oral mycobiome (COM) comprised 5 genera (of which Candida and Penicillium were shared between the two cohorts), (3) deceased abundance of the yeast Pichia coincided with increase in Candida abundance, suggesting an antagonistic association between these two fungi. To confirm this antagonistic interaction, we performed additional studies and showed that: (4) Pichia spent media (PSM) inhibited Candida growth, adherence, germination, and its ability to form biofilms, (5) this anti-Candida activity was Pichia
specific. (6) PSM exhibited broad antifungal activity inhibiting Cryptococcus, Aspergillus and Fusarium as well. Next, (7) used a murine model of OC and showed that PSM-treatment reduced Candida infection in vivo, as shown by reduction in tongue fungal load and histological evaluation. (8) Treatment of PSM with proteinase-K abrogated its anti-biofilm activity, while metabolites extracted from PSM had no effect on Candida, showing that the active component/s of PSM is proteinaceous in nature. Next, (9) we performed proteomics analysis of PSM and found 13 proteins with a high match score (indicating strong identity match), including 6 glycolytic enzymes, 3 transcription factors, a plasma-membrane ATPase, a glucanase, and a serine proteinase. Since, glucanase and proteinase were shown to mediate the inhibitory activity of Pichia against plant fungi we hypothesize that the anti-Candida activity of PSM is mediated by these proteins. Finally, (10) exposure to pepstatin A (proteinase inhibitor) abrogated the anti-Candida activity of PSM implicating proteinase in PSM inhibition. In this application, we will purify and characterize the glucanase/proteinase proteins, determine their mechanism/s of action, and validate their efficacy using a murine model of OC. The specific aims of the current proposal are: Aim 1. Purify and characterize glucanase and proteinase proteins of PSM. Aim 2. Determine the mechanism/s by which Pichia glucanase/proteinase inhibit Candida. Aim 3. Determine the efficacy of Pichia glucanase/proteinase in vivo. Understanding the mechanism/s by which Pichia proteins inhibit these organisms is critical in providing insight into the pathogenesis and control of fungal infections.
描述(由申请人提供):口腔念珠菌病(OC,由念珠菌引起)是免疫抑制患者的主要并发症,包括感染HIV、癌症和糖尿病的患者以及婴儿。OC的风险因素之一是使用抗生素,已知抗生素会改变微生物植物群。念珠菌和口腔微生物组成员之间的相互作用尚未研究。我们进行了初步研究以:(a)表征口腔细菌微生物组(细菌组)和口腔真菌微生物组(真菌组),以及(B)确定细菌组/真菌组的变化是否影响念珠菌定殖。我们展示了:(1)核心口腔细菌组(COB)由14个属组成,其中13个属是常见的;(2)核心口腔真菌组(COM)由5个属组成,其中念珠菌属和青霉属是两个群体共有的;(3)酵母毕赤酵母菌的丰度下降与念珠菌属丰度增加相一致,表明这两种真菌之间存在拮抗关系。为了证实这种拮抗作用,我们进行了额外的研究,结果表明:(4)毕赤酵母菌废培养基(PSM)抑制念珠菌的生长,粘附,萌发及其形成生物膜的能力,(5)这种抗念珠菌活性是毕赤酵母菌
特定. (6)PSM对隐球菌属、曲霉属和镰刀菌属均有较好的抑菌活性。接下来,(7)使用OC的鼠模型,并显示PSM治疗减少了体内念珠菌感染,如舌真菌负荷减少和组织学评价所示。(8)用蛋白酶-K处理PSM废除了其抗生物膜活性,而从PSM提取的代谢产物对念珠菌没有影响,表明PSM的活性组分本质上是蛋白质。接下来,(9)我们对PSM进行了蛋白质组学分析,发现了13个具有高匹配分数(指示强同一性匹配)的蛋白质,包括6个糖酵解酶、3个转录因子、质膜ATP酶、葡聚糖酶和丝氨酸蛋白酶。由于葡聚糖酶和蛋白酶被证明介导毕赤酵母对植物真菌的抑制活性,我们推测PSM的抗念珠菌活性是由这些蛋白质介导的。最后,(10)暴露于胃酶抑素A(蛋白酶抑制剂)消除了PSM的抗念珠菌活性,表明蛋白酶参与了PSM抑制。在本申请中,我们将纯化和表征葡聚糖酶/蛋白酶蛋白,确定其作用机制,并使用OC小鼠模型验证其功效。本提案的具体目标是:目标1。对PSM的葡聚糖酶和蛋白酶蛋白进行了纯化和鉴定。目标2.确定毕赤酵母葡聚糖酶/蛋白酶抑制念珠菌的机制。目标3。确定毕赤酵母葡聚糖酶/蛋白酶在体内的功效。了解毕赤酵母蛋白抑制这些生物体的机制对于深入了解真菌感染的发病机制和控制至关重要。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mahmoud A Ghannoum其他文献
Time to Think Antifungal Resistance Increased Antifungal Resistance Exacerbates the Burden of Fungal Infections Including Resistant Dermatomycoses
是时候考虑抗真菌耐药性了 抗真菌耐药性的增加会加剧包括耐药性皮肤真菌病在内的真菌感染的负担
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Thomas S McCormick;Mahmoud A Ghannoum - 通讯作者:
Mahmoud A Ghannoum
Mahmoud A Ghannoum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mahmoud A Ghannoum', 18)}}的其他基金
Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infection
用于全身和皮肤耳念珠菌感染的第二代真菌的开发和评估
- 批准号:
10561860 - 财政年份:2022
- 资助金额:
$ 39.63万 - 项目类别:
Polymicrobial interactions in Crohn's Disease
克罗恩病中的多种微生物相互作用
- 批准号:
10441347 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
Polymicrobial interactions in Crohn's Disease
克罗恩病中的多种微生物相互作用
- 批准号:
9973148 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
Polymicrobial interactions in Crohn's Disease
克罗恩病中的多种微生物相互作用
- 批准号:
10652329 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
Polymicrobial interactions in Crohn's Disease
克罗恩病中的多种微生物相互作用
- 批准号:
10223109 - 财政年份:2019
- 资助金额:
$ 39.63万 - 项目类别:
Mechanism of antifungal action of Pichia proteins
毕赤酵母蛋白的抗真菌作用机制
- 批准号:
8821602 - 财政年份:2014
- 资助金额:
$ 39.63万 - 项目类别:
Mechanism of antifungal action of Pichia proteins
毕赤酵母蛋白的抗真菌作用机制
- 批准号:
8671094 - 财政年份:2014
- 资助金额:
$ 39.63万 - 项目类别:
Mechanism of antifungal action of Pichia proteins
毕赤酵母蛋白的抗真菌作用机制
- 批准号:
8996475 - 财政年份:2014
- 资助金额:
$ 39.63万 - 项目类别:
Identification of early phase C. albicans biofilm proteins
早期白色念珠菌生物膜蛋白的鉴定
- 批准号:
8063533 - 财政年份:2007
- 资助金额:
$ 39.63万 - 项目类别:
Identification of early phase C. albicans biofilm proteins
早期白色念珠菌生物膜蛋白的鉴定
- 批准号:
7424061 - 财政年份:2007
- 资助金额:
$ 39.63万 - 项目类别:
相似海外基金
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 39.63万 - 项目类别:
Fellowship Programs